

May 17, 2021

Mr. Hassan Abdulrahman Al Serkal
Chief Executive Officer
Dubai Financial Market

Avigan phase 3 Clinical trials

Reference to the above mentioned subject; and in accordance with Chapter 10 of the Capital Markets Authority's bylaws of Law No. 7 of the year 2010 on Disclosure and Transparency Agility would like to announce:

Date	May 17, 2021
Company Name	Agility Public Warehousing Company KSCP "Agility"
Previous Disclosure date	February 1 st , 2021
Previous Disclosure Subject	Commenting on the News: Avigan shows effective results
Material Information	Global Response Aid (GRA), an affiliate of Agility, announced that a Phase 3 US-Canada clinical trial of Avigan®, an anti-viral drug, will continue amid signs the drug could be effective in treatment of patients with mild to moderate cases of COVID-19. Interim results of the trials indicate that Avigan®, the brand name for generic Favipiravir, could shorten recovery times and prevent progression of COVID-19 in patients in early stages of infection. The US-Canada clinical trial will continue into the summer. Dubai-based GRA holds joint rights to manufacture, market and distribute Avigan® outside of Japan, China and Russia.
Impact of the material information on the financial position of the company	There is no material impact as yet because the drug is not licensed or approved for treatment of COVID-19 in the United States or Canada.

Best Regards,



Tarek Abdul Aziz Sultan Al Essa
Vice Chairman and CEO

